Spectrum Pharmaceuticals, Inc. (SPPI) Scoops Up Allos Therapeutics, Inc. (ALTH) in Deal Worth $206 Million as Bladder Cancer Drug Fails Phase 3

4/5/2012 6:56:49 AM

(Reuters) - Spectrum Pharmaceuticals Inc (SPPI.O) said its experimental drug to treat bladder cancer failed to meet the main goals of late-stage trials, sending its shares down 16 percent in premarket trade.

The company was testing the drug apaziquone in two late-stage trials for non-muscle invasive bladder tumors.

The company also said it agreed to buy Allos Therapeutics (ALTH.O) for about $206 million.

Read at News Release

Read at Genetic Engineering News

Read at Nasdaq

Read at Reuters

Read at RTT News

Read at Canadian Business

Read Article at

Related Companies

News Categories

• News Release

• Genetic Engineering News

• Nasdaq